John Hanna

John Hanna MD has a strong background in drug safety and pharmacovigilance. John currently works as a Consultant pharmacovigilance and risk management for Drug Safety Consultant since May 2023. Prior to that, they held positions such as VP Union County Board of Health at TOWN OF UNION BOARD OF HEALTH starting from March 2021, Global Safety Physician at Biogen starting from January 2021, and VP Head of Drug Safety at Drug Safety starting from December 2019. John was also the Global Head of Drug Safety at Prolong Pharmaceuticals from November 2017, where they were responsible for all clinical drug safety and pharmacovigilance activities. Before that, they served as a Medical Safety Physician at Allergan from August 2015, where they provided support for safety in clinical development and post-marketing surveillance. Additionally, they held positions such as VP Head of Clinical Safety at Drug Safety Group, LLC from May 2022 to May 2023, Head of Drug Safety at Nimbus Therapeutics from August 2021 to May 2022, and Medical Safety Expert at Novartis/GSK Consumer Healthcare in 2015. John started their career as a Senior SciSME (Subject Matter Expert Pharmaceutical Labeling FDA PDLI-EI Program) at Reed Tech, Inc. from June 2011 to December 2014, where they supported the conversion of FDA approved Prescribing Information.

John Hanna MD has a diverse education history. John attended the University of Medicine and obtained a Doctor of Medicine (MD) and Master of Public Health (MPH) degree, specializing in General Surgery and General Medicine. Prior to this, they completed their high school education at Hudson Catholic High School in NJ in 1992. Later, they pursued their Doctor of Philosophy (PhD) degree at Temple University. The field of study for this degree is not specified.